Skip to main content
Premium Trial:

Request an Annual Quote

David Arnold, Gunter Thebeling, Fran Tuttle

Third Wave Technologies has appointed David Arnold to its board of directors. Arnold is a former VP and CTO of Kennametal, where he worked for 24 years.
 

 
Fluorotechnics has appointed Günter Thebeling to head its sales and marketing team. Thebeling formerly was strategic marketing director for proteomics products at GE Healthcare and was responsible for managing relationships with pharmaceutical partners and with scientific organizations such as the Human Proteome Organization.
 

 
Fran Tuttle has been appointed to join Xceed Molecular’s board of trustees. Tuttle is president and CEO of HX Diagnostics, and formerly was CEO of Protedyne, and senior VP of near patient testing at Bayer Diagnostics. Before that she worked at Chiron Diagnostics.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.